fig1
![Personalized T-cell therapy in liver transplanted patients with hepatitis B virus related hepatocellular carcinoma](https://image.oaes.cc/79f61fb3-b043-4724-9040-4244edc51a41/3447.fig.1.jpg)
Figure 1. Schematic illustrating the development of mRNA electroporated HBV-specific TCR redirected T cells. A: identification of HBV-specific antigens expressed on metastatic tumor through molecular approaches; B: activation and expansion of autologous T cells for T cell engineering; C: in vitro production of mRNA encoding HBV-specific TCRs; D: developing HBV-specific TCR-redirected T cells through electroporation activated T cells with desired mRNA; E: evaluation of TCR expression and functionality of modified T cell using tetramer staining and immune assays; F: modified TCR-T cells reinfused back to LT patient to specifically target and lyse HBV-infected HCC in a HLA restricted manner with no off-tumor side effects on the HBV-infected graft. TCR: T cell receptor; HBV: hepatitis B virus; LT: liver transplantation; HCC: hepatocellular carcinoma; HLA: human leukocyte antigen; MHC: major histocompatibility complex